banda transcan 2 2016ul

Title: High resolution project on prognosis and CARE of cancer patients.


Project Coordinator:
Milena SANT (Italy) Fondazione IRCCS Istituto Nazionale dei Tumori, Milan


Project Partners:
Karin M. G. HAUSTERMANS (Belgium) University Hospitals Leuven, Leuven
Pascale GROSCLAUDE (France ) Francim: Réseau Français des registres de cancer, Toulouse
Alexander KATALINIC (Germany) Institute for Cancer Epidemiology e.V., University Lübeck Cancer Registry of Schleswig-Holstein, Lübeck
Magdalena BIELSKA-LASOTA (Poland) National Institute of Public Health ñ National Institute of Hygiene (NIPHñNIH), Warszawa
Maja PRIMIC ZAKELI (Slovenia) Institute of Oncology Ljubljana, Ljubljana
Maria-José SANCHEZ-PEREZ (Spain) Granada Cancer Registry, Escuela Andaluza de Salùd Publica. CIBERESP. Instituto de Investigacion Biosanitaria. Granada


Project Abstract:
Cancer survival inequalities documented by EUROCARE need to be explained by Population Based Cancer Registry (CR) High Resolution (HR) studies that capture innovation in cancer diagnosis and treatment and investigate whether co-morbidities influence outcome and treatments. Main Aim: Study influence of patterns of care and co-morbidities on clinical outcomes in breast (BC) and colorectal cancer (CC) patients diagnosed in 2011-14 in some EU areas. Specific aims: Investigate influence of co-morbidity on treatment choice, adhesion to clinical guidelines, relapse and disease-free survival and their association with BC and CC prognostic characteristics. Additional aim: CRs possibility to access biobanks in their areas will be piloted through the validation of a plasma derived microRNA signature. Design &Work Plan. Each CR will recruit a sample of 500 cases per tumour site, and will abstract information on stage, diagnostic exams, morphology and bio-molecular subtype, treatment, co-morbidity and follow-up, from clinical records (as with HR study protocol). Data will be centralized and multivariable survival analyses will be carried out. In addition, a plasma-based microRNA signature predictive of distant metastatization in early stage BC will be validated using biobanks in partners areas. The project will be coordinated by the Fondazione IRCCS Istituto Nazionale dei Tumori and organised in 4 WPs. The research consortium includes CRs with past experience in HR studies, 1 basic research and 2 clinical teams, epidemiologists, public health experts.

(Project funded under JTC 2013)


TRANSCAN-2 News


PRE-ANNOUNCEMENT

The Fourth Joint Transnational Call 2017 (JTC 2017)

will be launched on December 5th, 2017

on: Translational Research on Rare Cancers

The list of participant funding organizations has been updated on November 21st

(FCT - Portugal has joined the call)

visit the page


JTC 2016

on: “Minimally and non-invasive methods for early detection and/or progression of cancer"

14 projects selected for funding 

visit the page


 

Newsletters

Newsletter 3, September 2017

Newsletter 2, April 2017

Newsletter 1, December 2016

 

To subscribe to TRANSCAN-2 newsletter mailing list please send an email to: This email address is being protected from spambots. You need JavaScript enabled to view it.

eu flagship

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643638.

Cookie consent script